Related Experiment Video
Updated: Apr 13, 2026

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
Considerations for patients awaiting heart transplantation-Insights from the UK experience
Guy A MacGowan1, David S Crossland1, Asif Hasan1
11 Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK ; 2 Institute of Medical Genetics, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK ; 3 Department of Paediatric Cardiology, 4 Department of Paediatric Cardiothoracic Surgery, 5 Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK.
Insights
The heart transplant waiting list is growing, especially with ventricular assist device (VAD) patients. Re-evaluating transplant criteria is crucial to prioritize patients who will benefit most from this scarce resource.
Area of Science:
- Cardiology
- Transplantation Medicine
- Medical Ethics
Background:
- The heart transplant waiting list has evolved, with an increasing number of patients supported by ventricular assist devices (VADs).
- Limited donor availability necessitates a re-evaluation of current heart transplant listing criteria.
- The survival benefit of heart transplantation for stable ambulatory heart failure patients requires further investigation.
Purpose of the Study:
- To address the need for effective models to predict heart transplant benefit in diverse patient groups.
- To explore criteria for prioritizing patients with VADs or adult congenital heart disease.
- To ensure fair allocation of scarce donor hearts to the sickest, most-benefiting recipients.
Main Methods:
- Review of current heart transplant waiting list demographics and patient profiles.
- Analysis of existing evidence on survival benefits for different heart failure patient categories.
- Conceptual framework development for prioritization models.
Main Results:
- Growing proportion of VAD patients on the heart transplant list.
- Uncertainty regarding optimal prioritization for stable VAD and adult congenital heart disease patients.
- Identification of a need for predictive models for transplant benefit.
Conclusions:
- Re-evaluation of heart transplant listing criteria is urgently needed due to changing patient demographics.
- Development of simple, effective models is essential for equitable allocation of donor hearts.
- Prioritization should focus on identifying patients with the greatest potential to benefit from transplantation.
Abstract:
The nature and size of the heart transplant waiting list has changed over recent years, most obviously with a larger number of patients on the list with ventricular assist devices (VADs). Given the limited numbers of available donors it is time to re-evaluate who is actually placed on the list. Evidence suggests that many patients with stable ambulatory heart failure might have a limited survival benefit from heart transplantation, so these patients may be an obvious target when considering how to reduce the size of the list. How stable VAD patients or adult congenital heart disease patients with declining symptoms should be prioritized for transplantation is unclear. Nevertheless we do need effective and simple models that can predict which of these disparate groups would benefit from transplantation so that we can fairly distribute this scarce commodity to the sickest patients that would benefit the most from transplantation.
More Related Videos
08:15Innovative Strategies for Organ Preservation in Heart Transplantation: Uniform Cooling Preservation and Ex-situ Normothermic Perfusion
Published on: November 28, 2025
07:08A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death
Published on: June 6, 2025
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VII: Pre and Post Operative Nursing Management